Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
IGF-1 LR3 reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
IGF-1 LR3 is a modified 83-amino-acid analogue of igf-1 of 83 amino acids. Native insulin-like growth factor-1. It retains the full 70-residue native sequence and adds a 13-residue N-terminal extension.
Two modifications relative to native IGF-1: an N-terminal arginine extension and a Glu3→Arg3 substitution. Together they reduce IGFBP-3 binding by roughly 1,000-fold, which is the entire design intent — it removes the binding-protein brake that normally regulates free ligand.
Reported to leave far more free ligand available to the IGF-1 receptor, activating PI3K-Akt-mTOR and MAPK-ERK signalling. It also activates the insulin receptor at roughly 1% the affinity of insulin. Vectra makes no claim as to mechanism or effect.
No human studies are recorded in our sources. The animal record includes Tomas FM et al., 'Long R3 IGF-I: potency and half-life in rats' (Growth Factors, 1993) and Jacobs JW et al. on IGFBP-3 interactions (J Endocrinol, 1997), both cited by title only without PMIDs.
Studied in IGF-1 receptor signalling and binding-protein interaction. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
No formal evidence rating, no human trial names, no participant counts and no PMIDs are recorded. Claims circulating about recovery or body-composition effects have no citation behind them in our sources.
Hypoglycaemia is the repeatedly identified concern, given the ~1% insulin-receptor affinity. Reported symptoms include shakiness, sweating, confusion and rapid heart rate. Our sources carry no formal contraindication list. Diabetes, concurrent glucose-lowering agents, malignancy and pregnancy are all unaddressed in them.
Lyophilised powder is stored in a freezer at -20°C. In-solution stability is solvent-dependent.
Our sources carry no CAS number, molecular formula, molecular weight, or letter sequence for IGF-1 LR3.
Not approved for human therapy and not legally compoundable. IGF-1 and its analogues are prohibited at all times by WADA under S2, covering peptide hormones and growth factors. They are detectable by serum IGF-1 measurement with isoform differentiation for 48–72 hours. No therapeutic, preventive, or diagnostic claims are made or implied.
Yes — in more than one way:
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.
IGF-1 LR3 reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
IGF-1 LR3 is a modified 83-amino-acid analogue of igf-1 of 83 amino acids. Native insulin-like growth factor-1. It retains the full 70-residue native sequence and adds a 13-residue N-terminal extension.
Two modifications relative to native IGF-1: an N-terminal arginine extension and a Glu3→Arg3 substitution. Together they reduce IGFBP-3 binding by roughly 1,000-fold, which is the entire design intent — it removes the binding-protein brake that normally regulates free ligand.
Reported to leave far more free ligand available to the IGF-1 receptor, activating PI3K-Akt-mTOR and MAPK-ERK signalling. It also activates the insulin receptor at roughly 1% the affinity of insulin. Vectra makes no claim as to mechanism or effect.
No human studies are recorded in our sources. The animal record includes Tomas FM et al., 'Long R3 IGF-I: potency and half-life in rats' (Growth Factors, 1993) and Jacobs JW et al. on IGFBP-3 interactions (J Endocrinol, 1997), both cited by title only without PMIDs.
Studied in IGF-1 receptor signalling and binding-protein interaction. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
No formal evidence rating, no human trial names, no participant counts and no PMIDs are recorded. Claims circulating about recovery or body-composition effects have no citation behind them in our sources.
Hypoglycaemia is the repeatedly identified concern, given the ~1% insulin-receptor affinity. Reported symptoms include shakiness, sweating, confusion and rapid heart rate. Our sources carry no formal contraindication list. Diabetes, concurrent glucose-lowering agents, malignancy and pregnancy are all unaddressed in them.
Lyophilised powder is stored in a freezer at -20°C. In-solution stability is solvent-dependent.
Our sources carry no CAS number, molecular formula, molecular weight, or letter sequence for IGF-1 LR3.
Not approved for human therapy and not legally compoundable. IGF-1 and its analogues are prohibited at all times by WADA under S2, covering peptide hormones and growth factors. They are detectable by serum IGF-1 measurement with isoform differentiation for 48–72 hours. No therapeutic, preventive, or diagnostic claims are made or implied.
Yes — in more than one way:
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.
Compatibility does not assert current availability. No preparation, ratio, or protocol guidance renders here.
Compatibility does not assert current availability. No preparation, ratio, or protocol guidance renders here.